Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers

Richard D. Huhn, Edward J. Yurkow, John G. Kuhn, Laura Clarke, Han Gunn, Debra Resta, Reena Shah, Laurie A. Myers, James R. Seibold

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Normal volunteers received subcutaneous injections of recombinant human interleukin-3 (rhIL-3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosage were 2.5, 5.0, and 7.5 μg/kg/day (n = 6 subjects per group). Adverse effects consisted predominantly of flu-like symptoms such as fever and headache. Mean area under the serum concentration-time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34+ cell counts were correlated with increases of colony-forming unit-granulocyte macrophage (peak, day 7).

Original languageEnglish (US)
Pages (from-to)32-41
Number of pages10
JournalClinical pharmacology and therapeutics
Issue number1
StatePublished - Jan 1995

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers'. Together they form a unique fingerprint.

Cite this